Prandin 2mg tablets

देश: यूनाइटेड किंगडम

भाषा: अंग्रेज़ी

स्रोत: MHRA (Medicines & Healthcare Products Regulatory Agency)

सक्रिय संघटक:

Repaglinide

थमां उपलब्ध:

Novo Nordisk Ltd

ए.टी.सी कोड:

A10BX02

INN (इंटरनेशनल नाम):

Repaglinide

डोज़:

2mg

फार्मास्यूटिकल फॉर्म:

Tablet

प्रशासन का मार्ग:

Oral

वर्ग:

No Controlled Drug Status

प्रिस्क्रिप्शन प्रकार:

Valid as a prescribable product

उत्पाद समीक्षा:

BNF: 06010203; GTIN: 5017954001514

सूचना पत्रक

_ _
1
PACKAGE LEAFLET: INFORMATION FOR THE USER
PRANDIN
® 0.5 MG TABLETS
PRANDIN
® 1 MG TABLETS
PRANDIN
® 2 MG TABLETS
Repaglinide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
–
Keep this leaflet. You may need to read it again.
–
If you have any further questions, ask your doctor or pharmacist.
–
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
–
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
WHAT PRANDIN
® IS AND WHAT IT IS USED FOR
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE PRANDIN
®
3.
HOW TO TAKE PRANDIN
®
4.
POSSIBLE SIDE EFFECTS
5.
HOW TO STORE PRANDIN
®
6.
CONTENTS OF THE PACK AND OTHER INFORMATION
1.
WHAT PRANDIN
® IS AND WHAT IT IS USED FOR
Prandin
®
is an _oral antidiabetic medicine containing repaglinide_ which helps
your pancreas produce
more insulin and thereby lower your blood sugar (glucose).
TYPE 2 DIABETES is a disease in which your pancreas does not make
enough insulin to control the
sugar in your blood or where your body does not respond normally to
the insulin it produces.
Prandin
®
is used to control type 2 diabetes in adults as an add-on to diet and
exercise: treatment is
usually started if diet, exercise and weight reduction alone have not
been able to control (or lower)
your blood sugar. Prandin
®
can also be given with metformin, another medicine for diabetes.
Prandin
®
has been shown to lower the blood sugar, which helps to prevent
complications from your
diabetes.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE PRANDIN
®
DO NOT TAKE PRANDIN
®
•
If you are ALLERGIC to repaglinide or any of the other ingredients in
this medicine (listed in
section 6).
•
If you have TYPE 1 DIABETES.
•
If the acid level in your blood is raised (DIABETIC KETOACIDOSIS).
•
If you have a SE

उत्पाद विशेषताएं

OBJECT 1
PRANDIN 0.5MG TABLETS
Summary of Product Characteristics Updated 10-Jun-2016 | Novo Nordisk
Limited
1. Name of the medicinal product
Prandin 0.5 mg tablets
Prandin 1 mg tablets
Prandin 2 mg tablets
2. Qualitative and quantitative composition
Each tablet contains 0.5 mg of repaglinide or 1 mg of repaglinide or 2
mg of repaglinide.
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Tablet
Repaglinide tablets are white (0.5 mg), yellow (1 mg), or
peach-coloured (2 mg), round and convex and
engraved with Novo Nordisk logo (Apis bull).
4. Clinical particulars
4.1 Therapeutic indications
Repaglinide is indicated in adults with type 2 diabetes mellitus whose
hyperglycaemia can no longer be
controlled satisfactorily by diet, weight reduction and exercise.
Repaglinide is also indicated in
combination with metformin in adults with type 2 diabetes mellitus who
are not satisfactorily controlled
on metformin alone.
Treatment should be initiated as an adjunct to diet and exercise to
lower the blood glucose in relation to
meals.
4.2 Posology and method of administration
Posology
Repaglinide is given preprandially and is titrated individually to
optimise glycaemic control. In addition
to the usual self-monitoring by the patient of blood and/or urinary
glucose, the patient's blood glucose
must be monitored periodically by the physician to determine the
minimum effective dose for the patient.
Glycosylated haemoglobin levels are also of value in monitoring the
patient's response to therapy.
Periodic monitoring is necessary to detect inadequate lowering of
blood glucose at the recommended
maximum dose level (i.e. primary failure) and to detect loss of
adequate blood glucose-lowering response
after an initial period of effectiveness (i.e. secondary failure).
Short-term administration of repaglinide may be sufficient during
periods of transient loss of control in
type 2 diabetic patients usually controlled well on diet.
Initial dose
The dosage should be determined by the physician, according to the
patie